transcriptional plasticity promotes primary acquired resistance bet inhibition 
following discovery brd4 non-oncogene addiction target acute myeloid leukaemia aml bromodomain extra terminal protein bet inhibitors explored promising therapeutic avenue numerous cancers- clinical trials reported single-agent activity advanced haematological malignancies mechanisms determining response bet inhibition remain poorly understood identify factors involved primary acquired bet resistance leukaemia perform chromatin-focused rnai screen sensitive mll-af9 nrasg12d-driven aml mouse model investigate dynamic transcriptional profiles sensitive resistantmouse human leukaemias screen shows suppression prc2 complex contrary effects contexts promotes bet inhibitor resistance aml prc2 suppression directly affect regulation brd4-dependent transcripts facilitates remodelling regulatory pathways restore transcription key targets myc similarly bet inhibition triggers acute myc repression human leukaemias regardless sensitivity resistant leukaemias uniformly characterized ability rapidly restore myc transcription process involves activation recruitment wnt signalling components compensate loss brd4 drive resistance various cancer models dynamic chromatin immunoprecipitation sequencing self-transcribing active regulatory region sequencing enhancer profiles reveal bet-resistant states characterized remodelled regulatory landscapes involving activation focal myc enhancer recruits wnt machinery response bet inhibition together results identify validate wnt signalling driver candidate biomarker primary acquired bet resistance leukaemia implicate rewiring transcriptional programs important mechanism promoting resistance bet inhibitors potentially chromatin-targeted therapies 
